Total antibodies and neutralizing ability of convalescent sera against three different strains of SARS-CoV-2
- Authors: Palyanova N.V.1, Adamenko L.S.1, Kurskaya O.G.1, Saroyan T.A.1, Solomatina M.V.1, Sobolev I.A.1, Shestopalov A.M.1
-
Affiliations:
- Federal Research Center for Fundamental and Translational Medicine
- Issue: Vol 70, No 1 (2025)
- Pages: 78-86
- Section: ORIGINAL RESEARCH
- URL: https://bakhtiniada.ru/0507-4088/article/view/287912
- DOI: https://doi.org/10.36233/0507-4088-290
- EDN: https://elibrary.ru/qcllgf
- ID: 287912
Cite item
Abstract
The aim of the study was to assess the level of humoral immunity to SARS-CoV-2 in COVID-19 convalescents.
Materials and methods. We used ELISA for antibody quantitation, microneutralization test using three SARS-CoV-2 strains for neutralizing activity measurement, Illumina MiSeq platform for NGS sequencing and NextClade resource for phylogenetic analysis.
Results. The mean concentration of antibody in convalescents was 133.42 ± 7.2 BAU/mL and the value depended on neither the gender and age of the patients, nor on the time elapsed since COVID-19 infection. The studied SARS-CoV-2 strains were sequenced and deposited in the international GISAID database. According to genetic analysis: EPI_ISL_19424272 phylogenetically belongs to the B1.1 clade, EPI_ISL_19424271 – to B.1.1.397 clade, EPI_ISL_19424270 – to Delta B.1.617.2.122. There were no significant differences in the neutralizing ability of convalescent sera (those who had been ill 2–3 months before the study) for the first two variants of SARS-CoV-2 and it was significantly reduced for the Delta variant, which appeared in the Novosibirsk region later.
Conclusions. The neutralizing activity of convalescent sera was the highest against those variants of the virus that the patient had recovered from, while was reduced or absent against the new variant. The antibody developed to the original variants of the SARS-CoV-2 may not be effective enough against newly emerging strains due to the emergence of mutations in the virus that allow it to evade previously developed humoral immune response.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Natalia V. Palyanova
Federal Research Center for Fundamental and Translational Medicine
Author for correspondence.
Email: natalia.palyanova@gmail.com
ORCID iD: 0000-0002-1783-5798
SPIN-code: 4975-4485
Scopus Author ID: 55983936800
ResearcherId: KAM-6786-2024
junior researcher
Russian Federation, 630117, NovosibirskLubov S. Adamenko
Federal Research Center for Fundamental and Translational Medicine
Email: aminisib@yandex.ru
ORCID iD: 0000-0001-6412-3622
junior researcher
Russian Federation, 630117, NovosibirskOlga G. Kurskaya
Federal Research Center for Fundamental and Translational Medicine
Email: kurskaya_og@mail.ru
ORCID iD: 0000-0002-1931-2026
Ph.D., Head of the Laboratory of Respiratory Viral Infections, Senior Researcher
Russian Federation, 630117, NovosibirskTereza A. Saroyan
Federal Research Center for Fundamental and Translational Medicine
Email: 111.st.13@rambler.ru
ORCID iD: 0000-0001-8071-5425
junior researcher
Russian Federation, 630117, NovosibirskMariya V. Solomatina
Federal Research Center for Fundamental and Translational Medicine
Email: solomatina.mariyav@yandex.com
ORCID iD: 0000-0003-0736-0271
Ph.D., senior researcher
Russian Federation, 630117, NovosibirskIvan A. Sobolev
Federal Research Center for Fundamental and Translational Medicine
Email: sobolev.riov@yandex.ru
ORCID iD: 0000-0002-4561-6517
Ph.D., Senior Researcher, Head of the Laboratory of Genomics and Virus Evolution
Russian Federation, 630117, NovosibirskAlexander M. Shestopalov
Federal Research Center for Fundamental and Translational Medicine
Email: shestopalov2@mail.ru
ORCID iD: 0000-0002-9734-0620
Ph.D., professor, Dr. of Sc., Honored Scientist of the Russian Federation, Director Research Institute of Virology FRC FTM
Russian Federation, 630117, NovosibirskReferences
- Balakhonov S.V., Dubrovina V.I., Chesnokova M.V., Voitkova V.V., Pyatidesyatnikova A.B., Bryukhova D.D., et al. Studying humoral immune response at mild and asymptomatic COVID-19 forms. Acta Biomedica Scientifica. 2020; 5(5): 26–30. https://doi.org/10.29413/ABS.2020-5.5.3 https://elibrary.ru/mvlnmh (in Russian)
- Machhi J., Herskovitz J., Senan A.M., Dutta D., Nath B., Oleynikov M.D., et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J. Neuroimmune Pharmacol. 2020; 15(3): 359–86. https://doi.org/10.1007/s11481-020-09944-5
- Palyanova N., Sobolev I., Alekseev A., Glushenko A., Kazachkova E., Markhaev A., et al. Genomic and epidemiological features of COVID-19 in the Novosibirsk region during the beginning of the pandemic. Viruses. 2022; 14(9): 2036. https://doi.org/10.3390/v14092036
- Novikova E.A., Petrova A.G., Moskaleva E.V., Vanyarkina A.S., Rychkova L.V. Retrospective of international serological studies on the formation and dynamics of the humoral immune response to SARS-CoV-2: from 2020 to 2021. Acta Biomedica Scientifica. 2021; 6(2): 47–57. https://doi.org/10.29413/ABS.2021-6.2.5 https://elibrary.ru/sbnnav (in Russian)
- Oktay Gültekin E., Gültekin O., Coskun A., Aksak T. Antibody response three months after SARS-CoV-2 infection. J. Med. Virol. 2022; 94(10): 4712–8. https://doi.org/10.1002/jmv.27909
- Palyanova N.V., Sobolev I.A., Palyanov A.Y., Kurskaya O.G., Komissarov A.B., Danilenko D.M. et al. The development of the SARS-CoV-2 epidemic in different regions of Siberia in the 2020–2022 Period. Viruses. 2023; 15(10): 2014. https://doi.org/10.3390/v15102014
- Tukhvatulin A.I., Dolzhikova I.V., Shcheblyakov D.V., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults. Lancet Reg. Health Eur. 2021; 11: 100241. https://doi.org/10.1016/j.lanepe.2021.100241
- Evseeva G.P., Lazareva M.A., Vlasova M.A., Nagovitsyna E.В., Suprun S.V., Telepneva R.S. et al. Assessment of the level of immune layer to SARS-CoV-2 in children under conditions of novel coronavirus infection COVID-19. Byulleten’ fiziologii i patologii dykhaniya. 2023; (88): 59–68. https://doi.org/10.36604/1998-5029-2023-88-59-68 https://elibrary.ru/lhyxot (in Russian)
- Wang K., Long Q.X., Deng H.J., Hu J., Gao Q.Z., Zhang G.J., et al. Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection. Clin. Infect. Dis. 2021; 73(3): e531–9. https://doi.org/10.1093/cid/ciaa1143
Supplementary files
